News

Investment agreement with Neuromedical

2020.05.17

We live longer and longer. Currently, there are around 900 million people over the age of 60 in the world, and this percentage is still growing, especially in developed countries. The increase in the number of older people also means the increase in the number of people suffering from old age diseases. An important health problem is neurodegenerative diseases, including Alzheimer’s disease. Nearly 47 million people affected by this disease live in the world. It is estimated that in 2023 there will be nearly 75 million, and by 2050 the number will reach about 131 million. The incidence of the disease increases with age – the number of cases doubles every six years. In Poland alone, around 500,000 people are affected by dementia, of which around 300,000 are caused by Alzheimer’s disease.

Medicine does not yet offer effective causal treatment. Treatment of Alzheimer’s disease currently means reducing or slowing down the development of its symptoms. The available methods are: pharmacotherapy, psychotherapy and neurostimulation, which is a currently developing therapeutic direction. Most neurostimulation research has so far focused on invasive methods in the treatment of drug-resistant epilepsy and migraines. Invasive methods, however, carry a significant risk of side effects. The VGuard system developed by Neuromedical is an globally innovative product for transdermal vagal nerve stimulation for people suffering from cognitive and memory disorders due to Alzheimer’s disease.

– “The VGuard system addresses a significant and constantly growing health problem. It combines the latest achievements of neurology with the simplicity of use. It also allows for very long-term use, which is not necessarily feasible in the case of pharmaceutical methods. Collecting and analyzing data provides the basis for continuous improvement. We see the great potential of this technology and are pleased with the cooperation that has just begun” – said Marcin Bielówka, managing partner at the INNOventure fund.

More information about Neuromedical can be found in  our portfolio.